Dilon Technologies

June 10, 2011 – Dilon Diagnostics introduced the U.S. Food and Drug Administration (FDA)-cleared Dilon 6800 Acella gamma camera system this week at the Society of Nuclear Medicine (SNM) annual meeting in San Antonio, Texas. To complement the Dilon 6800 standard field-of-view imaging system, the new camera will feature a much larger molecular breast imaging (MBI), which will make Dilon the first company in the industry to offer customers a choice in detector sizes.

April 13, 2011 – The U.S. Department of Energy has highlighted Dilon Diagnostics as a success story in the field of medical technology and innovation for commercializing the technologies of the national laboratories. According to the government agency, Dilon and similar entrepreneurs, "build the new industries of the 21st century, and help solve some of our toughest global challenges."

Dilon Diagnostics provides a complete system for breast-specific gamma imaging (BSGI) and biopsy guidance. The Dilon 6800 gamma camera supports the diagnostic procedure of molecular breast imaging, known as BSGI or MBI, with high-resolution digital imaging optimized for early breast cancer detection.

December 22, 2009 – The FDA has granted 510(k) clearance to a lesion-localization system for molecular imaging biopsy guidance. The GammaLoc (GL) is a complementary technology to Dilon Diagnostics’ 6800 Gamma Camera.

December 4, 2009 - Breast-Specific Gamma Imaging (BSGI) is a molecular breast imaging technique increasingly being used in the diagnostic workup of patients with indeterminate mammograms and has demonstrated the ability to detect cancers missed by mammography and ultrasound.